EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

2023 FDA TIDES (Peptides and Oligonucleotides) Harvest

Danah Al Shaer iD, Othman Al Musaimi iD, Fernando Albericio iD, Beatriz G de la Torre iD

Pharmaceuticals · 13.02.2024 · 17 (2) · 243

DOI: 10.3390/ph17020243 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 13.02.2024. Verfasst von Danah Al Shaer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Evotec (UK) Ltd., Abingdon OX14 4R, UK. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Newcastle University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A total of nine TIDES (pepTIDES and oligonucleoTIDES) were approved by the FDA during 2023. The four approved oligonucleotides are indicated for various types of disorders, including amyotrophic lateral sclerosis, geographic atrophy, primary hyperoxaluria type 1, and polyneuropathy of hereditary transthyretin-mediated amyloidosis. All oligonucleotides show chemically modified structures to enhance their stability and therapeutic effectiveness as antisense or aptamer oligomers. Some of them demonstrate various types of conjugation to driving ligands. The approved peptides comprise various structures, including linear, cyclic, and lipopeptides, and have diverse applications. Interestingly, the FDA has granted its first orphan drug designation for a peptide-based drug as a highly selective chemokine antagonist. Furthermore, Rett syndrome has found its first-ever core symptoms treatment, which is also peptide-based. Here, we analyze the TIDES approved in 2023 on the basis of their chemical structure, medical target, mode of action, administration route, and common adverse effects.

Schlagwörter

Stichwörter der Autor:innen

FDA approvalsavacincaptad pegoldrugseplontersenflotufolastat Fmotixafortidenedosiranoligonucleotidespeptidesrezafungintofersentrofinetidezilucoplan

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Evotec (UK) Ltd., Abingdon OX14 4R, UK.
  • School of Pharmacy, Faculty of Medical Sciences, Newcastle upon Tyne NE1 7RU, UK.
  • Department of Chemical Engineering, Imperial College London, London SW7 2AZ, UK.
  • School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa.
  • CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain.
  • KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa.

ORCID-Profile: Danah Al Shaer, Othman Al Musaimi, Fernando Albericio, Beatriz G de la Torre

Förderung

  • Newcastle University

Zitieren

APA

Al Shaer, D., Al Musaimi, O., Albericio, F., & de la Torre, B. G. (2024). 2023 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals, 17(2), 243. https://doi.org/10.3390/ph17020243

Vancouver

Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. 2023 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals. 2024;17(2):243. doi:10.3390/ph17020243

BibTeX
@article{AlShaer2024,
  author = {Al Shaer, Danah and Al Musaimi, Othman and Albericio, Fernando and de la Torre, Beatriz G},
  title = {2023 FDA TIDES (Peptides and Oligonucleotides) Harvest},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {2},
  pages = {243},
  doi = {10.3390/ph17020243}
}
Kostenlos starten →